Monopar Therapeutics Stock Alpha and Beta Analysis
| MNPR Stock | USD 19.71 0.71 3.74% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Monopar Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Monopar Therapeutics over a specified time horizon. Remember, high Monopar Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Monopar Therapeutics' market risk premium analysis include:
Beta (4.07) | Alpha 10.37 | Risk 77.17 | Sharpe Ratio 0.14 | Expected Return 10.47 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Monopar |
Monopar Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Monopar Therapeutics market risk premium is the additional return an investor will receive from holding Monopar Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Monopar Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Monopar Therapeutics' performance over market.| α | 10.37 | β | -4.07 |
Monopar Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Monopar Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Monopar Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Monopar Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Monopar Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Monopar Therapeutics shares will generate the highest return on investment. By understating and applying Monopar Therapeutics stock market price indicators, traders can identify Monopar Therapeutics position entry and exit signals to maximize returns.
Monopar Therapeutics Return and Market Media
The median price of Monopar Therapeutics for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 5.17 with a coefficient of variation of 81.67. The daily time series for the period is distributed with a sample standard deviation of 6.73, arithmetic mean of 8.24, and mean deviation of 5.75. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Cittadine Andrew of 12000 shares of Monopar Therapeutics at 0.6443 subject to Rule 16b-3 | 09/03/2024 |
2 | Disposition of 13841 shares by Cittadine Andrew of Monopar Therapeutics subject to Rule 16b-3 | 09/24/2024 |
3 | Disposition of 1791 shares by Cittadine Andrew of Monopar Therapeutics subject to Rule 16b-3 | 09/30/2024 |
4 | Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers | 10/15/2024 |
5 | Monopar Therapeutics Shares Surge on Partnership with Alexion | 10/24/2024 |
6 | Whats Going On With Monopar Therapeutics Shares Friday | 10/25/2024 |
7 | Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock | 10/28/2024 |
8 | Will Monopar Therapeutics continue to fall in November | 10/29/2024 |
9 | Insider Purchase CFO Karthik Radhakrishnan Acquires Shares of Monopar Therapeutics Inc | 10/30/2024 |
10 | Monopar Therapeutics Inc Reports Q3 2024 GAAP EPS of -0.37 and Net Loss of 1.3 Million | 11/08/2024 |
11 | Monopar Therapeutics stock target lifted, buy rating on AstraZeneca deal | 11/11/2024 |
12 | Acquisition by Cittadine Andrew of 12000 shares of Monopar Therapeutics at 0.6397 subject to Rule 16b-3 | 11/14/2024 |
13 | Jones Trading raises Monopar Therapeutics target to 37 | 11/19/2024 |
About Monopar Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Monopar or other stocks. Alpha measures the amount that position in Monopar Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Monopar Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Monopar Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Monopar Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Monopar Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Monopar Therapeutics. Please utilize our Beneish M Score to check the likelihood of Monopar Therapeutics' management manipulating its earnings.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Monopar Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.